Drug Class
hmg coa reductase inhibitors

last updated 06/30/2014

1. CPIC Guideline for simvastatin and SLCO1B1

Summary

The FDA recommends against 80mg daily simvastatin dosage. In patients with the C allele at SLCO1B1 rs4149056, there are modest increases in myopathy risk even at lower simvastatin doses (40mg daily); if optimal efficacy is not achieved with a lower dose, alternate agents should be considered.

Annotation

October 2014 Update

Advance online publication 9 July 2014.

  • The 2014 update of CPIC guideline regarding SLCO1B1 and simvastatin-induced myopathy, has been published in Clinical Pharmacology and Therapeutics. CPIC extensively reviewed the literature from February 2011 to December 2013 and concluded the dosing recommendations provided in the 2012 CPIC guideline for SLCO1B1 and simvastatin-induced myopathy have not changed. However, this updated guideline also provides a brief review regarding SLCO1B1 genotype and risk of myopathy for other statins. Furthermore, comprehensive translation tables mapping SLCO1B1 genotypes to coded genotype/phenotype summaries, EHR priority result notation and interpretation (consultation) text were created to facilitate incorporation of SLCO1B1 pharmacogenetics into an electronic health record with clinical decision support.

  • This guideline is applicable to:

    • adult patients
    • pediatric patients
  • Excerpt from the 2014 simvastatin dosing guideline:

    • "For simvastatin, the evidence linking myopathy to rs4149056 in SLCO1B1 is of high quality, and this association has been reproduced in randomized trials and clinical practice-based cohorts. Conversely, the association of rs4149056 with myopathy has been less compelling for other statins. We therefore focus this guideline on simvastatin."

"In 2011 and updated in 2013, the FDA added warnings to the simvastatin product label to direct providers away from initiating at the 80 mg simvastatin dose. "

"At lower simvastatin doses (e.g., 40 mg daily), it is our position that SLCO1B1 genotype (if available) could be used to warn providers about modest increases in myopathy risk for patients with a C allele at rs4149056. In these circumstances, we recommend a lower dose of simvastatin or use an alternative statin (e.g. pravastatin or rosuvastatin) and we also highlight the potential utility of routine CK surveillance (Table 2). If patients with a C allele at rs4149056 do not achieve optimal LDL cholesterol-lowering efficacy with a lower dose (e.g. 20 mg) of simvastatin, we recommend the prescribing physician consider an alternate statin based on (i) potency differences (i.e., use a lower dose of a higher potency statin such as atorvastatin, rosuvastatin, or pitavastatin), (ii) drug-drug interactions (e.g., boceprevir, clarithromycin, cyclosporine, strong CYP3A4 inhibitors, etc.), and (iii) relevant co-morbidities (e.g., trauma, significant renal impairment, post-solid organ transplant, thyroid disease etc.)."

"At the time of this writing, there are no data available regarding SLCO1B1 genotype effects on simvastatin response or myopathy in pediatric patient populations, although there is no reason to suspect that the polymorphisms in SLCO1B1 will affect simvastatin's metabolism differently in children compared to adults."

Table 1: Recommended dosing of simvastatin based on SLCO1B1 phenotype

Adapted from Table 1 and 2 of the 2014 guideline update manuscript.

PhenotypeExamples of diplotypes aGenotype at rs4149056Implications for simvastatinDosing recommendations for simvastatin b,cClassification of recommendations d
Normal function, Homozygous wild-type (two normal function alleles)*1a/*1a, *1a/*1b, *1b/*1bTTNormal myopathy riskPrescribe desired starting dose and adjust doses of simvastatin based on disease-specific guidelines.Strong
Intermediate function, Heterozygous (one normal function allele plus one decreased function allele)*1a/*5, *1a/*15, *1a/*17, *1b/*5, *1b/*15, *1b/*17TCIntermediate myopathy riskPrescribe a lower dose or consider an alternative statin (e.g. pravastatin or rosuvastatin); consider routine CK surveillance.Strong
Low function, Homozygous variant or mutant (two decreased function alleles)*5/*5, *5/*15, *5/*17, *15/*15, *15/*17, *17/*17CCHigh myopathy riskPrescribe a lower dose or consider an alternative statin (e.g. pravastatin or rosuvastatin); consider routine CK surveillance.Strong

CK, creatine kinase.

a SLCO1B1 alleles are often named using __ allele nomenclature, representing various SNPs alone or in combination (http://www.pharmgkb.org/gene/PA134865839#tabview=tab4&subtab=33) (2014 Update Supplemental Table S1) that are associated with low SLCO1B1 protein expression or function (2014 Update Supplemental Table S2). The minor C allele at rs4149056 is contained within SLCO1B1*5 (rs4149056 alone) as well as the *15 and *17 haplotypes and is associated with lower plasma clearance of simvastatin. The magnitude of this effect is similar for *5, *15, and *17 haplotypes.

b In all cases, the potential for drug-drug interaction should be evaluated prior to initiating a prescription.

c FDA recommends against 80mg (unless already tolerated 12 months).

d See Supplementary Materials (text section entitled "Levels of Evidence") online for additional details regarding the three-tiered system used to grade the quality of evidence.

July 2012

Advance online publication May 2012.



Annotated Labels

  1. FDA Label for atorvastatin and LDLR
  2. FDA Label for fluvastatin
  3. FDA Label for lovastatin
  4. FDA Label for pitavastatin
  5. FDA Label for pravastatin and LDLR
  6. FDA Label for pravastatin and APOE
  7. FDA Label for rosuvastatin and LDLR,SLCO1B1
  8. FDA Label for simvastatin
  9. PMDA Label for atorvastatin and LDLR
  10. HCSC Label for atorvastatin and LDLR
  11. HCSC Label for rosuvastatin and LDLR

last updated 10/25/2013

1. FDA Label for atorvastatin and LDLR

Actionable PGx

Summary

Although the atorvastatin drug label does not specifically mention genetic testing, one of the indications listed is for the treatment of familial hypercholesterolemia, a genetically determined condition caused by mutations in the low density lipoprotein receptor (LDLR); one of the drug's mechanisms of action is increasing LDLR cell surface expression.

There's more of this label. Read more.





last updated 08/09/2016

5. FDA Label for pravastatin and LDLR

Actionable PGx

Summary

The FDA-approved drug label for pravastatin (PRAVACHOL) states that the drug is intended for patients with familial hypercholesterolemia (Fredrickson Type IIa), among other indications. Familial hypercholesterolemia is commonly caused by mutations in the LDLR (low density lipoprotein receptor) gene; pravastatin has only been evaluated in patients with heterozygous familial hypercholesterolemia (i.e. patients with only one abnormal copy of the LDLR gene).

There's more of this label. Read more.


last updated 12/20/2013

6. FDA Label for pravastatin and APOE

Informative PGx

Summary

The FDA drug label contains pharmacogenetic information regarding response results in patients with APOE genotype E2/E2 and Fredrickson Type III dysbetalipoproteinemia. This drug-biomarkers pair was previously in the FDA's "Table of Pharmacogenomic Biomarkers in Drug Labels" but has subsequently been removed, and replaced by pravastatin and LDLR.

There's more of this label. Read more.


last updated 08/05/2016

7. FDA Label for rosuvastatin and LDLR,SLCO1B1

Actionable PGx

Summary

Although the rosuvastatin (CRESTOR) drug label does not specifically mention genetic testing, one of the indications listed is for the treatment of homozygous or heterozygous familial hypercholesterolemia, a genetically determined condition often caused by mutations in the low density lipoprotein receptor gene (LDLR). These mutations lead to reduced LDL receptor activity.

There's more of this label. Read more.



last updated 01/26/2015

9. PMDA Label for atorvastatin and LDLR

Actionable PGx

Summary

The PMDA package insert for atorvastatin notes that it should be administered in patients with homozygous familial hypercholesterolemia, a genetically determined condition caused by mutations in the low density lipoprotein receptor gene (LDLR).

There's more of this label. Read more.


last updated 07/28/2016

10. HCSC Label for atorvastatin and LDLR

Actionable PGx

Summary

The product monograph for atorvastatin states that it is indicated for hyperlipidemic and dyslipidemic conditions, including homozygous and heterozygous familial hypercholesterolemia, genetically determined conditions caused by mutations in the low density lipoprotein receptor (LDLR)

There's more of this label. Read more.


last updated 06/08/2015

11. HCSC Label for rosuvastatin and LDLR

Actionable PGx

Summary

The product monograph for rosuvastatin states that it is indicated for hyperlipidemic and dyslipidemic conditions, including homozygous familial hypercholesterolemia, a genetically determined condition caused by mutations in the low density lipoprotein receptor (LDLR)

There's more of this label. Read more.


PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for hmg coa reductase inhibitors

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA No Variant Annotations available
rs10046 NC_000015.10:g.51210789G>A, NC_000015.9:g.51502986G>A, NG_007982.1:g.132810C>T, NM_000103.3:c.*19C>T, NM_031226.2:c.*19C>T, XM_005254190.1:c.*19C>T, XM_005254191.1:c.*19C>T, XM_005254192.1:c.*19C>T, XR_932222.1:n.99-67194G>A, rs3169030, rs386509163, rs59469642
G > A
SNP
No VIP available CA VA
rs10455872 NC_000006.11:g.161010118A>G, NC_000006.12:g.160589086A>G, NG_016147.1:g.82290T>C, NM_005577.2:c.3947+467T>C, XM_005266985.1:c.3785+467T>C
A > G
SNP
No VIP available CA VA
rs1045642 NC_000007.13:g.87138645A>G, NC_000007.14:g.87509329A>G, NG_011513.1:g.208920T>C, NM_000927.4:c.3435T>C, NP_000918.2:p.Ile1145=, rs10239679, rs11568726, rs117328163, rs17210003, rs2229108, rs386513066, rs60023214, rs9690664
A > G
SNP
I1145I
No VIP available No Clinical Annotations available VA
rs1050450 NC_000003.11:g.49394834G>A, NC_000003.12:g.49357401G>A, NG_012264.1:g.5958C>T, NM_000581.2:c.599C>T, NM_201397.1:c.*581C>T, NP_000572.2:p.Pro200Leu, rs11549656, rs61730124
G > A
SNP
P200L
No VIP available CA No Variant Annotations available
rs1062033 NC_000015.10:g.51255741C>G, NC_000015.9:g.51547938C>G, NG_007982.1:g.87858G>C, NM_000103.3:c.-38-12791G>C, NM_031226.2:c.-38-12791G>C, XM_005254191.1:c.-38-12791G>C, XR_932222.1:n.99-22242C>G, rs17647575, rs3169029, rs56591429, rs57401428, rs60544338
C > G
SNP
No VIP available CA VA
rs1063320 NC_000006.11:g.29798749C=, NC_000006.11:g.29798749C>G, NC_000006.12:g.29830972C=, NC_000006.12:g.29830972C>G, NG_029039.1:g.8994C=, NG_029039.1:g.8994C>G, NM_002127.5:c.*233C=, NM_002127.5:c.*233C>G, NT_113891.3:g.1314548G=, NT_113891.3:g.1314548G>C, NT_167244.2:g.1096598G=, NT_167244.2:g.1096598G>C, NT_167245.1:g.1099370C=, NT_167245.1:g.1099370C>G, NT_167245.2:g.1093785C=, NT_167245.2:g.1093785C>G, NT_167246.1:g.1099078C=, NT_167246.1:g.1099078C>G, NT_167246.2:g.1093458C=, NT_167246.2:g.1093458C>G, NT_167247.1:g.1099028C=, NT_167247.1:g.1099028C>G, NT_167247.2:g.1093443C=, NT_167247.2:g.1093443C>G, NT_167248.2:g.1093752G=, NT_167248.2:g.1093752G>C, NT_167249.2:g.1137017G=, NT_167249.2:g.1137017G>C, XM_005249055.1:c.*233C=, XM_005249055.1:c.*233C>G, XM_005249056.1:c.*233C>G, XM_005249056.1:c.*233G>C, XM_005249057.1:c.*448C>G, XM_005249057.1:c.*448G>C, XM_005249058.1:c.*233C=, XM_005249058.1:c.*233C>G, XM_005272810.1:c.*247G=, XM_005272810.1:c.*247G>C, XM_005274964.1:c.*233C=, XM_005274964.1:c.*233C>G, XM_005274965.1:c.*233C=, XM_005274965.1:c.*233C>G, XM_005274966.1:c.*448C>G, XM_005274966.1:c.*448G>C, XM_005274967.1:c.*233C=, XM_005274967.1:c.*233C>G, XM_005275119.1:c.*233C=, XM_005275119.1:c.*233C>G, XM_005275120.1:c.*233C>G, XM_005275120.1:c.*233G>C, XM_005275121.1:c.*448C>G, XM_005275121.1:c.*448G>C, XM_005275122.1:c.*233C>G, XM_005275122.1:c.*233G>C, XM_005275246.1:c.*233C=, XM_005275246.1:c.*233C>G, XM_005275247.1:c.*233C=, XM_005275247.1:c.*233C>G, XM_005275248.1:c.*448C>G, XM_005275248.1:c.*448G>C, XM_005275249.1:c.*233C=, XM_005275249.1:c.*233C>G, XM_005275394.1:c.*247G=, XM_005275394.1:c.*247G>C, XM_005275549.1:c.*247G=, XM_005275549.1:c.*247G>C, XM_005275550.1:c.*247C>G, XM_005275550.1:c.*247G>C, XM_005275551.1:c.*462C>G, XM_005275551.1:c.*462G>C, XM_005275552.1:c.*247G=, XM_005275552.1:c.*247G>C, XM_011547651.1:c.*233C=, XM_011547651.1:c.*233C>G, XM_011547882.1:c.*233C=, XM_011547882.1:c.*233C>G, XM_011548048.1:c.*233C=, XM_011548048.1:c.*233C>G, XM_011548236.1:c.*247G=, XM_011548236.1:c.*247G>C, XM_011548237.1:c.*247G=, XM_011548237.1:c.*247G>C, XM_011548430.1:c.*247G=, XM_011548430.1:c.*247G>C, XM_011548431.1:c.*247G=, XM_011548431.1:c.*247G>C, XR_241896.1:n.1859C=, XR_241896.1:n.1859C>G, XR_246963.1:n.1793G=, XR_246963.1:n.1793G>C, XR_247353.1:n.1859C=, XR_247353.1:n.1859C>G, XR_247370.1:n.1859C=, XR_247370.1:n.1859C>G, XR_247389.1:n.1859C=, XR_247389.1:n.1859C>G, XR_247402.1:n.1793G=, XR_247402.1:n.1793G>C, XR_247423.1:n.1851G=, XR_247423.1:n.1851G>C, rs115928989, rs117512550, rs1632929, rs16867727, rs17185496, rs3204385, rs386485817, rs58677621, rs9258500
C > C
C > G
SNP
No VIP available CA VA
rs1128503 NC_000007.13:g.87179601A>G, NC_000007.14:g.87550285A>G, NG_011513.1:g.167964T>C, NM_000927.4:c.1236T>C, NP_000918.2:p.Gly412=, rs116989428, rs17276907, rs2032587, rs2229105, rs28365046, rs386518005, rs58257317
A > G
SNP
G412G
No VIP available No Clinical Annotations available VA
rs11591147 NC_000001.10:g.55505647G>T, NC_000001.11:g.55039974G>T, NG_009061.1:g.5428G>T, NM_174936.3:c.137G>T, NP_777596.2:p.Arg46Leu, NR_110451.1:n.-248G>T
G > T
SNP
R46L
No VIP available No Clinical Annotations available VA
rs11807862 NC_000001.10:g.3279268T>A, NC_000001.11:g.3362704T>A, NG_029576.1:g.298527T>A, NM_022114.3:c.439-22448T>A, NM_199454.2:c.439-22448T>A, XM_005244772.1:c.439-22445T>A, XM_005244772.3:c.439-22445T>A, XM_005244773.1:c.439-22445T>A, XM_005244773.3:c.439-22445T>A, XM_005244774.1:c.439-22445T>A, XM_005244774.3:c.439-22445T>A, XM_006710814.2:c.439-22445T>A, XM_011541944.1:c.439-22445T>A, XM_011541945.1:c.-114-22448T>A, rs57382713
T > A
SNP
No VIP available CA VA
rs118192172 NC_000019.10:g.38457545C>T, NC_000019.9:g.38948185C>T, NG_008866.1:g.28846C>T, NM_000540.2:c.1840C>T, NM_001042723.1:c.1840C>T, NP_000531.2:p.Arg614Cys, NP_001036188.1:p.Arg614Cys, XM_006723317.1:c.1840C>T, XM_006723319.1:c.1840C>T, XM_011527204.1:c.1837C>T, XM_011527205.1:c.1840C>T, XP_006723380.1:p.Arg614Cys, XP_006723382.1:p.Arg614Cys, XP_011525506.1:p.Arg613Cys, XP_011525507.1:p.Arg614Cys, rs28933996
C > T
SNP
R614C
No VIP available CA VA
rs11868035 NC_000017.10:g.17715101G>A, NC_000017.11:g.17811787G>A, NG_007101.2:g.135315G>A, NG_029029.1:g.30225C>T, NM_001005291.2:c.*835C>T, NM_004176.4:c.*835C>T, NM_030665.3:c.*1806G>A, XM_005256772.1:c.*835C>T, XM_005256772.3:c.*835C>T, XM_005256773.1:c.*835C>T, XM_005256774.1:c.*835C>T, XM_006721570.2:c.*835C>T, XM_011523998.1:c.*835C>T, XM_011523999.1:c.*835C>T, XR_429821.2:n.4294-3C>T, rs13306740, rs60796536
G > A
SNP
No VIP available CA VA
rs12654264 NC_000005.10:g.75352778A>T, NC_000005.9:g.74648603A>T, NG_011449.1:g.20611A>T, NM_000859.2:c.1368+1176A>T, NM_001130996.1:c.1368+1176A>T, XM_005248492.1:c.1428+1176A>T, XM_011543357.1:c.1428+1176A>T, XM_011543358.1:c.1368+1176A>T, XM_011543359.1:c.1428+1176A>T, rs17562575, rs56464192, rs58426549
A > T
SNP
No VIP available CA VA
rs13064411 NC_000003.11:g.113046640A>G, NC_000003.12:g.113327793A>G, NM_001164496.1:c.4143T>C, NP_001157968.1:p.Asp1381=, XM_005247616.1:c.4275T>C, XM_005247617.1:c.1848T>C, XM_005247617.2:c.1848T>C, XM_006713696.1:c.4275T>C, XM_006713697.1:c.4122T>C, XM_011512975.1:c.4275T>C, XM_011512976.1:c.4143T>C, XM_011512977.1:c.3903T>C, XM_011512978.1:c.3594T>C, XM_011512979.1:c.3243T>C, XP_005247673.1:p.Asp1425=, XP_005247674.1:p.Asp616=, XP_006713759.1:p.Asp1425=, XP_006713760.1:p.Asp1374=, XP_011511277.1:p.Asp1425=, XP_011511278.1:p.Asp1381=, XP_011511279.1:p.Asp1301=, XP_011511280.1:p.Asp1198=, XP_011511281.1:p.Asp1081=, XR_427370.1:n.4800T>C, XR_427371.2:n.4800T>C, rs117025946, rs60450591
A > G
SNP
D1381D
No VIP available CA VA
rs1346268 NC_000015.10:g.45380831T>C, NC_000015.9:g.45673029T>C, NG_011674.1:g.2952A>G, XM_011521450.1:c.32-262A>G, XM_011521451.1:c.36-272A>G, rs60883720
T > C
SNP
No VIP available No Clinical Annotations available VA
rs137852808 NC_000002.11:g.175612912G>C, NC_000002.12:g.174748184G>C, NG_008172.1:g.21289C>G, NM_000079.3:c.1314C>G, NM_001039523.2:c.1389C>G, NP_000070.1:p.Cys438Trp, NP_001034612.1:p.Cys463Trp
G > C
SNP
C438W
No VIP available CA VA
rs1532624 NC_000016.10:g.56971567C>A, NC_000016.9:g.57005479C>A, NG_008952.1:g.14645C>A, NM_000078.2:c.658+186C>A, NM_001286085.1:c.658+186C>A, XM_005255776.1:c.658+186C>A, XM_006721124.2:c.658+186C>A, rs17238065, rs386536007, rs59150318
C > A
SNP
No VIP available No Clinical Annotations available VA
rs17171676 NC_000007.13:g.40340629A>C, NC_000007.14:g.40301030A>C, NG_023422.1:g.171055A>C, NM_001193311.1:c.742-15730A>C, NM_001193312.1:c.598-15730A>C, NM_001193313.1:c.742-15730A>C, NM_024728.2:c.631-15730A>C, XM_006715775.2:c.742-15730A>C, XM_011515525.1:c.742-15730A>C, XM_011515526.1:c.664-15730A>C, XM_011515527.1:c.598-15730A>C, XM_011515528.1:c.742-15730A>C, XM_011515529.1:c.598-15730A>C, XM_011515530.1:c.742-15730A>C
A > C
SNP
No VIP available CA VA
rs1719247 NC_000015.10:g.45328787C>T, NC_000015.9:g.45620985C>T, rs59060754
C > T
SNP
No VIP available CA No Variant Annotations available
rs17238540 NC_000005.10:g.75359673T>G, NC_000005.9:g.74655498T>G, NG_011449.1:g.27506T>G, NM_000859.2:c.2457+117T>G, NM_001130996.1:c.2298+117T>G, XM_005248492.1:c.2517+117T>G, XM_011543357.1:c.2517+117T>G, XM_011543358.1:c.2457+117T>G, XM_011543359.1:c.2358+117T>G, rs59500163
T > G
SNP
No VIP available CA No Variant Annotations available
rs17244841 NC_000005.10:g.75347030A>T, NC_000005.9:g.74642855A>T, NG_011449.1:g.14863A>T, NM_000859.2:c.451-174A>T, NM_001130996.1:c.451-174A>T, XM_005248492.1:c.511-174A>T, XM_011543357.1:c.511-174A>T, XM_011543358.1:c.451-174A>T, XM_011543359.1:c.511-174A>T, rs60168925
A > T
SNP
No VIP available No Clinical Annotations available VA
rs17381194 NC_000012.11:g.90011095T>C, NC_000012.12:g.89617318T>C, NG_029485.1:g.43750A>G, NM_001001323.1:c.1830-279A>G, NM_001682.2:c.1830-279A>G, XM_005268918.1:c.1830-279A>G, XM_005268919.1:c.1830-279A>G, XM_005268920.1:c.1830-279A>G, XM_005268921.1:c.1830-279A>G, XM_011538407.1:c.1830-279A>G, XM_011538408.1:c.1830-279A>G, XM_011538409.1:c.1830-279A>G, XM_011538410.1:c.1830-279A>G, XM_011538411.1:c.1830-279A>G, XM_011538412.1:c.1830-279A>G, XR_944556.1:n.2292-279A>G, rs57218851
T > C
SNP
No VIP available CA VA
rs1799983 NC_000007.13:g.150696111T>G, NC_000007.14:g.150999023T>G, NG_011992.1:g.12965T>G, NM_000603.4:c.894T>G, NM_001160109.1:c.894T>G, NM_001160110.1:c.894T>G, NM_001160111.1:c.894T>G, NP_000594.2:p.Asp298Glu, NP_001153581.1:p.Asp298Glu, NP_001153582.1:p.Asp298Glu, NP_001153583.1:p.Asp298Glu, XM_006716002.2:c.894T>G, XP_006716065.1:p.Asp298Glu, rs11266811, rs13238975, rs13305983, rs13308813, rs17173672, rs3730304, rs57135373
T > G
SNP
D298E
No VIP available CA No Variant Annotations available
rs1935349 NC_000010.10:g.92594343C>T, NC_000010.11:g.90834586C>T, NG_029218.1:g.28329G>A, NM_000872.4:c.539+22547G>A, NM_019859.3:c.539+22547G>A, NM_019860.3:c.539+22547G>A, rs60894291
C > T
SNP
No VIP available No Clinical Annotations available VA
rs2075650 NC_000019.10:g.44892362A>G, NC_000019.9:g.45395619A>G, NG_042854.1:g.6143A>G, NM_001128916.1:c.275-31A>G, NM_001128917.1:c.275-31A>G, NM_006114.2:c.275-31A>G, XM_005258411.1:c.275-31A>G, XM_005258411.2:c.275-31A>G, rs60321974
A > G
SNP
No VIP available No Clinical Annotations available VA
rs2231142 NC_000004.11:g.89052323G>T, NC_000004.12:g.88131171G>T, NG_032067.2:g.105152C>A, NM_001257386.1:c.421C>A, NM_004827.2:c.421C>A, NP_001244315.1:p.Gln141Lys, NP_004818.2:p.Gln141Lys, XM_005263354.1:c.421C>A, XM_005263354.2:c.421C>A, XM_005263355.1:c.421C>A, XM_005263355.2:c.421C>A, XM_005263356.1:c.421C>A, XM_005263356.2:c.421C>A, XM_011532420.1:c.421C>A, XP_005263411.1:p.Gln141Lys, XP_005263412.1:p.Gln141Lys, XP_005263413.1:p.Gln141Lys, XP_011530722.1:p.Gln141Lys, rs12721641, rs28365035, rs3736117, rs52809243, rs58973676
G > T
SNP
Q141K
No VIP available CA No Variant Annotations available
rs2289105 NC_000015.10:g.51215311T>C, NC_000015.9:g.51507508T>C, NG_007982.1:g.128288A>G, NM_000103.3:c.859-79A>G, NM_031226.2:c.859-79A>G, XM_005254190.1:c.859-79A>G, XM_005254191.1:c.859-79A>G, XM_005254192.1:c.682-79A>G, XR_932222.1:n.99-62672T>C, rs17601199, rs57755827
T > C
SNP
No VIP available CA VA
rs2306283 NC_000012.11:g.21329738A>G, NC_000012.12:g.21176804A>G, NG_011745.1:g.50611A>G, NM_006446.4:c.388A>G, NP_006437.3:p.Asn130Asp, rs17389242, rs52832430, rs60767041
A > G
SNP
N130D
No VIP available CA VA
rs2900478 NC_000012.11:g.21368797T>A, NC_000012.12:g.21215863T>A, NG_011745.1:g.89670T>A, NM_006446.4:c.1498-1256T>A, rs17382943
T > A
SNP
No VIP available CA VA
rs352046 NC_000004.11:g.74864550G>C, NC_000004.12:g.73998833G>C, NM_002994.4:c.-252C>G, XR_938874.1:n.61G>C, rs353017, rs3854134, rs57250141
G > C
SNP
No VIP available No Clinical Annotations available VA
rs35599367 NC_000007.13:g.99366316G>A, NC_000007.14:g.99768693G>A, NG_008421.1:g.20493C>T, NM_001202855.2:c.522-191C>T, NM_017460.5:c.522-191C>T, XM_011515841.1:c.522-191C>T, XM_011515842.1:c.522-191C>T, rs45581939, rs62471940
G > A
SNP
No VIP available No Clinical Annotations available VA
rs3764261 NC_000016.10:g.56959412C>A, NC_000016.9:g.56993324C>A, NG_008952.1:g.2490C>A, rs386585771, rs52828654, rs57153281
C > A
SNP
No VIP available No Clinical Annotations available VA
rs3846662 NC_000005.10:g.75355259A>G, NC_000005.9:g.74651084A>G, NG_011449.1:g.23092A>G, NM_000859.2:c.1722+45A>G, NM_001130996.1:c.1564-106A>G, XM_005248492.1:c.1782+45A>G, XM_011543357.1:c.1782+45A>G, XM_011543358.1:c.1722+45A>G, XM_011543359.1:c.1624-106A>G, rs17238505, rs17562582, rs386587624, rs56538861, rs59397732
A > G
SNP
No VIP available CA VA
rs402007 NC_000021.8:g.28217320C>G, NC_000021.9:g.26845001C>G, NM_006988.4:c.-47G>C, rs59674914
C > G
SNP
No VIP available CA VA
rs4149056 NC_000012.11:g.21331549T>C, NC_000012.12:g.21178615T>C, NG_011745.1:g.52422T>C, NM_006446.4:c.521T>C, NP_006437.3:p.Val174Ala, rs52816141, rs60037639
T > C
SNP
V174A
No VIP available No Clinical Annotations available VA
rs4253728 NC_000022.10:g.46610067G>A, NC_000022.11:g.46214170G>A, NG_012204.1:g.68569G>A, NM_001001928.2:c.209-1003G>A, NM_005036.4:c.209-1003G>A, XM_005261653.1:c.209-1003G>A, XM_005261654.1:c.209-1003G>A, XM_005261655.1:c.209-1003G>A, XM_005261655.2:c.209-1003G>A, XM_005261656.1:c.209-1003G>A, XM_005261656.2:c.209-1003G>A, XM_005261657.1:c.209-1003G>A, XM_005261658.1:c.209-1003G>A, XM_006724269.2:c.209-1003G>A, XM_006724270.2:c.209-1003G>A, XM_011530239.1:c.209-1003G>A, XM_011530240.1:c.209-1003G>A, XM_011530241.1:c.209-1003G>A, XM_011530242.1:c.209-1003G>A, XM_011530243.1:c.209-1003G>A, XM_011530244.1:c.-198-1003G>A, XM_011530245.1:c.-198-1003G>A, XR_244379.1:n.432-1003G>A, XR_937869.1:n.524-1003G>A, XR_937870.1:n.523-1003G>A, rs17242080, rs56473198, rs56722050
G > A
SNP
No VIP available CA VA
rs445925 NC_000019.10:g.44912383G>A, NC_000019.9:g.45415640G>A, NG_012859.1:g.2720G>A, XM_005258855.1:c.-2189G>A, XM_005258855.2:c.-2189G>A, rs116971620, rs386593216, rs487804
G > A
SNP
No VIP available CA VA
rs4693075 NC_000004.11:g.84192168G>C, NC_000004.12:g.83271015G>C, NG_015825.1:g.18900C>G, NM_015697.7:c.779-1022C>G, XM_005262926.1:c.425-1022C>G, XM_005262927.1:c.299-1022C>G, XM_011531855.1:c.779-1022C>G, XM_011531856.1:c.779-1022C>G, XM_011531857.1:c.779-1022C>G, XM_011531858.1:c.779-1022C>G, XM_011531859.1:c.779-1022C>G, XM_011531860.1:c.779-1022C>G, XM_011531861.1:c.779-1022C>G, XM_011531862.1:c.779-1022C>G, XM_011531863.1:c.779-1022C>G, XM_011531864.1:c.779-1022C>G, XM_011531865.1:c.779-1022C>G, XM_011531866.1:c.779-1022C>G, XM_011531867.1:c.425-1022C>G, XR_427543.2:n.938-1022C>G, XR_938721.1:n.949-1022C>G, rs58141687
G > C
SNP
No VIP available No Clinical Annotations available VA
rs4693570 NC_000004.11:g.84091851T>C, NC_000004.12:g.83170698T>C, XM_011531855.1:c.1376-31192A>G, XM_011531867.1:c.1022-31192A>G, rs60171905
T > C
SNP
No VIP available No Clinical Annotations available VA
rs4823613 NC_000022.10:g.46598307A>G, NC_000022.11:g.46202410A>G, NG_012204.1:g.56809A>G, NM_001001928.2:c.208+3819A>G, NM_005036.4:c.208+3819A>G, XM_005261653.1:c.208+3819A>G, XM_005261654.1:c.208+3819A>G, XM_005261655.1:c.208+3819A>G, XM_005261655.2:c.208+3819A>G, XM_005261656.1:c.208+3819A>G, XM_005261656.2:c.208+3819A>G, XM_005261657.1:c.208+3819A>G, XM_005261658.1:c.208+3819A>G, XM_006724269.2:c.208+3819A>G, XM_006724270.2:c.208+3819A>G, XM_011530239.1:c.208+3819A>G, XM_011530240.1:c.208+3819A>G, XM_011530241.1:c.208+3819A>G, XM_011530242.1:c.208+3819A>G, XM_011530243.1:c.208+3819A>G, XM_011530244.1:c.-199+3819A>G, XM_011530245.1:c.-199+3819A>G, XR_244379.1:n.431+3819A>G, XR_937869.1:n.523+3819A>G, XR_937870.1:n.522+3819A>G, rs5767571, rs58091507, rs74281148
A > G
SNP
No VIP available No Clinical Annotations available VA
rs533556 NC_000011.10:g.116870856A>C, NC_000011.9:g.116741572A>C, NM_001281748.1:c.1261-455T>G, NM_001281749.1:c.1594-455T>G, NM_025164.4:c.1738-455T>G, XM_005271481.1:c.1738-455T>G, XM_005271481.2:c.1738-455T>G, XM_005271482.1:c.1420-455T>G, XM_005271482.3:c.1594-455T>G, XM_005271483.1:c.1594-455T>G, XM_005271484.1:c.1564-455T>G, XM_005271484.3:c.1738-455T>G, XM_005271485.1:c.-705T>G, XM_005271485.2:c.-705T>G, XM_005271486.1:c.-705T>G, XM_011542721.1:c.1738-455T>G, XM_011542722.1:c.1738-455T>G, XM_011542723.1:c.1261-455T>G, XM_011542724.1:c.1261-455T>G, XM_011542725.1:c.1261-455T>G, XM_011542726.1:c.1738-455T>G, rs2270391, rs59533686
A > C
SNP
No VIP available CA VA
rs5443 NC_000012.11:g.6954875C>T, NC_000012.12:g.6845711C>T, NG_009100.1:g.10501C>T, NM_001297571.1:c.822C>T, NM_002075.3:c.825C>T, NP_001284500.1:p.Ser274=, NP_002066.1:p.Ser275=, NW_003871083.2:g.47295C>T, XM_005253679.1:c.825C>T, XM_005253680.1:c.822C>T, XM_005253681.1:c.702-6C>T, XM_005277751.1:c.825C>T, XM_005277752.1:c.822C>T, XM_005277753.1:c.702-6C>T, XM_011520953.1:c.825C>T, XM_011520954.1:c.822C>T, XM_011521027.1:c.*1818G>A, XM_011521028.1:c.*1818G>A, XM_011521029.1:c.*2036G>A, XM_011521030.1:c.*1969G>A, XP_005253736.1:p.Ser275=, XP_005253737.1:p.Ser274=, XP_005277808.1:p.Ser275=, XP_005277809.1:p.Ser274=, XP_011519255.1:p.Ser275=, XP_011519256.1:p.Ser274=, rs2230334, rs3138516, rs57419337, rs6489738
C > T
SNP
S274S
No VIP available No Clinical Annotations available VA
rs5883 NC_000016.10:g.56973441C>T, NC_000016.9:g.57007353C>T, NG_008952.1:g.16519C>T, NM_000078.2:c.861C>T, NM_001286085.1:c.750+1358C>T, NP_000069.2:p.Phe287=, XM_005255776.1:c.750+1358C>T, XM_006721124.2:c.*1222C>T, rs12720934, rs17245729, rs60749799
C > T
SNP
F287F
No VIP available CA VA
rs646776 NC_000001.10:g.109818530C>T, NC_000001.11:g.109275908C>T, NM_001408.2:c.*1859C>T, XM_005270580.1:c.*1726C>T, XM_005270580.3:c.*1726C>T, rs1624712, rs386602928, rs58595816
C > T
SNP
No VIP available CA VA
rs6535454 NC_000004.11:g.84191031A>G, NC_000004.12:g.83269878A>G, NG_015825.1:g.20037T>C, NM_015697.7:c.894T>C, NP_056512.5:p.Asp298=, XM_005262926.1:c.540T>C, XM_005262927.1:c.414T>C, XM_011531855.1:c.894T>C, XM_011531856.1:c.894T>C, XM_011531857.1:c.894T>C, XM_011531858.1:c.894T>C, XM_011531859.1:c.894T>C, XM_011531860.1:c.894T>C, XM_011531861.1:c.894T>C, XM_011531862.1:c.894T>C, XM_011531863.1:c.894T>C, XM_011531864.1:c.894T>C, XM_011531865.1:c.894T>C, XM_011531866.1:c.894T>C, XM_011531867.1:c.540T>C, XP_005262983.1:p.Asp180=, XP_005262984.1:p.Asp138=, XP_011530157.1:p.Asp298=, XP_011530158.1:p.Asp298=, XP_011530159.1:p.Asp298=, XP_011530160.1:p.Asp298=, XP_011530161.1:p.Asp298=, XP_011530162.1:p.Asp298=, XP_011530163.1:p.Asp298=, XP_011530164.1:p.Asp298=, XP_011530165.1:p.Asp298=, XP_011530166.1:p.Asp298=, XP_011530167.1:p.Asp298=, XP_011530168.1:p.Asp298=, XP_011530169.1:p.Asp180=, XR_427543.2:n.1053T>C, XR_938721.1:n.1064T>C, rs17589288, rs17850400, rs17851821, rs58091204
A > G
SNP
D298D
No VIP available No Clinical Annotations available VA
rs672348 NC_000019.10:g.45781076T>G, NC_000019.9:g.46284334T>G, NG_009784.1:g.6482A>C, NM_001081560.2:c.160+1117A>C, NM_001081562.2:c.160+1117A>C, NM_001081563.2:c.-1017A>C, NM_001288764.1:c.180-695A>C, NM_001288765.1:c.-1569A>C, NM_001288766.1:c.160+1117A>C, NM_004409.4:c.160+1117A>C, XM_005258605.1:c.180-695A>C, XM_005258606.1:c.160+1117A>C, XM_005258607.1:c.-1017A>C, XR_243908.1:n.299-695A>C, XR_243909.1:n.298+1117A>C, XR_243910.1:n.298+1117A>C
T > G
SNP
No VIP available CA VA
rs708272 NC_000016.10:g.56962376G>A, NC_000016.9:g.56996288G>A, NG_008952.1:g.5454G>A, NM_000078.2:c.118+279G>A, NM_001286085.1:c.118+279G>A, XM_005255776.1:c.118+279G>A, XM_006721124.2:c.118+279G>A, rs17237904, rs17290342, rs57207652
G > A
SNP
No VIP available CA No Variant Annotations available
rs749292 NC_000015.10:g.51266534G>A, NC_000015.9:g.51558731G>A, NG_007982.1:g.77065C>T, NM_000103.3:c.-38-23584C>T, NM_031226.2:c.-38-23584C>T, XM_005254191.1:c.-38-23584C>T, XR_932220.1:n.4170G>A, XR_932221.1:n.4170G>A, XR_932222.1:n.99-11449G>A, rs60112531
G > A
SNP
No VIP available CA VA
rs9806699 NC_000015.10:g.45448194G>A, NC_000015.9:g.45740392G>A, XM_011522289.1:c.-478G>A, rs58677873
G > A
SNP
No VIP available No Clinical Annotations available VA
rs9930761 NC_000016.10:g.56973280T>C, NC_000016.9:g.57007192T>C, NG_008952.1:g.16358T>C, NM_000078.2:c.751-51T>C, NM_001286085.1:c.750+1197T>C, XM_005255776.1:c.750+1197T>C, XM_006721124.2:c.*1061T>C, rs56950713
T > C
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
  • statin
  • statins
Trade Names
Brand Mixture Names

PharmGKB Accession Id

PA133950441

Other Vocabularies

Drugs And Small Molecules

The following have been classified under this therapeutic category:

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Statin Pathway - Generalized, Pharmacokinetics
    Representation of the superset of all genes involved in the transport, metabolism and clearance of statin class drugs.
  1. Statin Pathway, Pharmacodynamics
    Genes involved in mediating statin effects on hepatic cholesterol metabolism and consequent effects on plasma lipoprotein transport.

External Pathways

Links to non-PharmGKB pathways.

PharmGKB contains no links to external pathways for this drug. To report a pathway, click here.

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

No related drugs are available.

Curated Information ?

Publications related to hmg coa reductase inhibitors: 145

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Muscle rupture associated with statin use. British journal of clinical pharmacology. 2016. Ekhart C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol lowering. Pharmacogenomics. 2016. Leusink Maarten, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The effect of genetic variation in PCSK9 on the LDL-cholesterol response to statin therapy. The pharmacogenomics journal. 2016. Feng Q, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Seventeen years of statin pharmacogenetics: a systematic review. Pharmacogenomics. 2016. Leusink Maarten, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015. Santa-Maria Cesar A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Role of rs3846662 and HMGCR alternative splicing in statin efficacy and baseline lipid levels in familial hypercholesterolemia. Pharmacogenetics and genomics. 2015. Leduc Valerie, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Type of LDLR mutation and the pharmacogenetics of familial hypercholesterolemia treatment. Pharmacogenomics. 2015. Santos Paulo Caleb Junior Lima, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The JUPITER Trial. Circulation. 2015. Mora Samia, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid. Pharmacogenetics and genomics. 2015. Choi Hee Youn, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Individual and Combined Associations of Genetic Variants in CYP3A4, CYP3A5, and SLCO1B1 With Simvastatin and Simvastatin Acid Plasma Concentrations. Journal of cardiovascular pharmacology. 2015. Luzum Jasmine A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cardiovascular pharmacogenomics: current status and future directions. Journal of human genetics. 2015. Roden Dan M. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
ABCG2 gene polymorphisms as risk factors for atorvastatin adverse reactions: a case-control study. Pharmacogenomics. 2015. Mirošević Skvrce Nikica, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Low-Density Lipoprotein Particle Number Is Associated With Cardiovascular Events Among Those Not Classified Into Statin Benefit Groups. Journal of the American College of Cardiology. 2015. Melander Olle, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach. Pharmaceutical research. 2015. Tsamandouras Nikolaos, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. European heart journal. 2015. Stroes Erik S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
GATM polymorphism associated with the risk for statin-induced myopathy does not replicate in case-control analysis of 715 dyslipidemic individuals. Cell metabolism. 2015. Luzum Jasmine A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Statins are associated with a reduced risk of cholangiocarcinoma: a population-based case-control study. British journal of clinical pharmacology. 2015. Peng Yen-Chun, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?. European journal of clinical pharmacology. 2015. Birmingham Bruce K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet. 2015. Mega Jessica L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Report of New Haplotype for ABCC2 Gene: rs17222723 and rs8187718 in cis. The Journal of molecular diagnostics : JMD. 2015. Pratt Victoria M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration Adverse Event Reporting System. British journal of clinical pharmacology. 2015. Raschi Emanuel, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States. European journal of clinical pharmacology. 2015. Birmingham Bruce K, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The rs13064411 polymorphism in the WDR52 gene, associated with PCSK9 levels, modifies statin-induced changes in serum total and LDL cholesterol levels. Pharmacogenetics and genomics. 2015. de Keyser Catherine E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
SLCO1B1 genetic variants, long-term low-density lipoprotein cholesterol levels and clinical events in patients following cardiac catheterization. Pharmacogenomics. 2015. Li Josephine H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mechanisms and assessment of statin-related muscular adverse effects. British journal of clinical pharmacology. 2014. Moßhammer Dirk, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A polymorphism in HLA-G modifies statin benefit in asthma. The pharmacogenomics journal. 2014. Naidoo D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
No association between CYP3A4*22 and statin effectiveness in reducing the risk for myocardial infarction. Pharmacogenomics. 2014. Leusink Maarten, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Identification of the effect of multiple polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid using a population-modeling approach. Clinical pharmacology and therapeutics. 2014. Tsamandouras N, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Expression and activity of ABCG2, but not ABCB1 or OATP1B1, are associated with cholesterol levels: evidence from in vitro and in vivo experiments. Pharmacogenomics. 2014. To Kenneth Kw, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review. Genetics in medicine : official journal of the American College of Medical Genetics. 2014. Canestaro William J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2. European journal of clinical pharmacology. 2014. Ferrari Marco, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacoepidemiologic and in Vitro Evaluation of Potential Drug-Drug Interactions of Sulfonylureas with Fibrates and Statins. British journal of clinical pharmacology. 2014. Schelleman H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol. Mayo Clinic proceedings. 2014. Bielinski Suzette J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenomics of sterol synthesis and statin use in schizophrenia subjects treated with antipsychotics. Pharmacogenomics. 2014. Vassas Thomas J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nature communications. 2014. Postmus Iris, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Statin use in asthmatics on inhaled corticosteroids is associated with decreased risk of emergency department visits. Current medical research and opinion. 2013. Tse Sze Man, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. Pharmacogenetics and genomics. 2013. de Keyser Catherine E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Statin Exposure is Associated with Decreased Asthma-Related Emergency Department Visits and Oral Corticosteroid Use. American journal of respiratory and critical care medicine. 2013. Tse Sze Man, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Characterization of Statin Dose-response within Electronic Medical Records. Clinical pharmacology and therapeutics. 2013. Wei Wei-Qi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Statin induced changes in gene expression in EBV-transformed and native B-cells. Human molecular genetics. 2013. Bolotin Eugene, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Cholesteryl Ester Transfer Protein Polymorphisms, Statin Use, and Their Impact on Cholesterol Levels and Cardiovascular Events. Clinical pharmacology and therapeutics. 2013. Leusink M, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circulation. Cardiovascular genetics. 2013. DeGorter Marianne K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacometabolomics of Statin Response. Clinical pharmacology and therapeutics. 2013. Krauss Ronald M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
SLCO1B1 Genetic Variant Associated With Statin-Induced Myopathy: A Proof of Concept Study Using the Clinical Practice Research Datalink (CPRD). Clinical pharmacology and therapeutics. 2013. Carr Daniel F, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature. 2013. Mangravite Lara M, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients. Pharmacogenomics. 2013. Lee Hon-Kit, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic variation in the PPARA gene is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. Pharmacogenomics. 2013. de Keyser Catherine E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Providing patients with pharmacogenetic test results affects adherence to statin therapy: results of the Additional KIF6 Risk Offers Better Adherence to Statins (AKROBATS) trial. The pharmacogenomics journal. 2013. Charland S L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Relationship of sex to diabetes risk in statin trials. Diabetes care. 2013. Goodarzi Mark O, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-analysis of 30 467 individuals from both randomized control trials and observational studies and association with coronary artery disease outcome during statin treatment. Pharmacogenetics and genomics. 2013. Donnelly Louise A, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy. American heart journal. 2013. Danik Jacqueline S, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Impact of OATP1B1, MDR1, and CYP3A4 Expression in Liver and Intestine on Interpatient Pharmacokinetic Variability of Atorvastatin in Obese Subjects. Clinical pharmacology and therapeutics. 2013. Ulvestad M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gene-gene-environment interactions between drugs, transporters, receptors, and metabolizing enzymes: Statins, SLCO1B1, and CYP3A4 as an example. Journal of pharmaceutical sciences. 2013. Sadee Wolfgang. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Correction: RHOA Is a Modulator of the Cholesterol-Lowering Effects of Statin. PLoS genetics. 2013. Medina Marisa W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP3A4/5 combined genotype analysis for predicting statin dose requirement for optimal lipid control. Drug metabolism and drug interactions. 2013. Kitzmiller Joseph Paul, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Amlodipine - Not a Significant Contributor to Clopidogrel Non-Response?. Heart (British Cardiac Society). 2013. Kreutz Rolf P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics and cardiovascular disease--implications for personalized medicine. Pharmacological reviews. 2013. Johnson Julie A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association between polymorphisms of eNOS and GPx-1 genes, activity of free-radical processes and in-stent restenosis. Molecular and cellular biochemistry. 2012. Shuvalova Yu A, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Intronic variants in SLCO1B1 related to statin-induced myopathy are associated with the low-density lipoprotein cholesterol response to statins in Chinese patients with hyperlipidaemia. Pharmacogenetics and genomics. 2012. Hu Miao, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Transgenic mouse model reveals an unsuspected role of the acetylcholine receptor in statin-induced neuromuscular adverse drug reactions. The pharmacogenomics journal. 2012. Grajales-Reyes G E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cardiovascular pharmacogenomics: current status and future directions-report of a national heart, lung, and blood institute working group. Journal of the American Heart Association. 2012. Musunuru Kiran, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions. Pharmacogenomics. 2012. Feng Qiping, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Increased frequency of DRB1*11:01 in anti-HMG-CoA reductase-associated autoimmune myopathy. Arthritis care & research. 2012. Mammen Andrew L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Mechanisms of statin-induced myalgia assessed by physiogenomic associations. Atherosclerosis. 2011. Ruaño Gualberto, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. European journal of clinical pharmacology. 2011. Santos Paulo Caleb Junior Lima, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The effects of a SNP in SLCO1B1 on the pharmacodynamics of pravastatin. British journal of clinical pharmacology. 2011. Martin Nicholas G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic Influence in Statin Intolerance. Clinical pharmacology and therapeutics. 2011. Puccetti L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Transporter-mediated drug-drug interactions. Pharmacogenomics. 2011. Müller Fabian, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics: the genetics of variable drug responses. Circulation. 2011. Roden Dan M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Transporter-Mediated Drug Uptake and Efflux: Important Determinants of Adverse Drug Reactions. Clinical pharmacology and therapeutics. 2011. Zolk O, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy. Clinical pharmacology and therapeutics. 2011. Sadee W, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenetics and genomics. 2011. Marciante Kristin D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. The Journal of infectious diseases. 2011. Ganesan Anuradha, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PharmGKB summary: methotrexate pathway. Pharmacogenetics and genomics. 2011. Mikkelsen Torben S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Single nucleotide polymorphisms in genes that are associated with a modified response to statin therapy: the Rotterdam Study. The pharmacogenomics journal. 2011. de Keyser C E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic variants in the KIF6 region and coronary event reduction from statin therapy. Human genetics. 2011. Li Yonghong, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. The pharmacogenomics journal. 2011. Brunham L R, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Common Nonsynonymous Substitutions in SLCO1B1 Predispose to Statin Intolerance in Routinely Treated Individuals With Type 2 Diabetes: A Go-DARTS Study. Clinical pharmacology and therapeutics. 2010. Donnelly L A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathies. Molecular genetics and metabolism. 2011. Vladutiu Georgirene D, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Variants of ADAMTS1 modify the effectiveness of statins in reducing the risk of myocardial infarction. Pharmacogenetics and genomics. 2010. Peters Bas J M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of central obesity, low high-density lipoprotein cholesterol and C-reactive protein polymorphisms on C-reactive protein levels during treatment with Rosuvastatin (10 mg Daily). The American journal of cardiology. 2010. Hu Miao, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Impact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2010. Rotta Marcello, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
KIF6 polymorphism as a predictor of risk of coronary events and of clinical event reduction by statin therapy. The American journal of cardiology. 2010. Li Yonghong, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction. Pharmacogenomics. 2010. Peters Bas J M, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study. Atherosclerosis. 2010. Puccetti Luca, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Physiogenomic analysis of statin-treated patients: domain-specific counter effects within the ACACB gene on low-density lipoprotein cholesterol?. Pharmacogenomics. 2010. Ruaño Gualberto, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer. Cancer prevention research (Philadelphia, Pa.). 2010. Lipkin Steven M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. The pharmacogenomics journal. 2010. Wang D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Common sequence variants in pharmacodynamic and pharmacokinetic pathway-related genes conferring LDL cholesterol response to statins. Pharmacogenomics. 2010. Chien Kuo-Liong, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Skeletal muscle cell MHC I expression: implications for statin-induced myopathy. Muscle & nerve. 2010. Singh Pratibha, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. The pharmacogenomics journal. 2010. Romaine S P R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genome-wide association of lipid-lowering response to statins in combined study populations. PloS one. 2010. Barber Mathew J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The pharmacogenetics of statin therapy: when the body aches, the mind will follow. Journal of the American College of Cardiology. 2009. Rossi Joseph S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A highly annotated whole-genome sequence of a Korean individual. Nature. 2009. Kim Jong-Il, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
APOE gene polymorphisms and response to statin therapy. The pharmacogenomics journal. 2009. Zintzaras E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Statin regulation of CYP3A4 and CYP3A5 expression. Pharmacogenomics. 2009. Willrich Maria Alice Vieira, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The SLCO1B1*5 genetic variant is associated with statin-induced side effects. Journal of the American College of Cardiology. 2009. Voora Deepak, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Impact of apolipoprotein A5 variants on statin treatment efficacy. Pharmacogenomics. 2009. Hubacek Jaroslav A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics and stroke. Stroke; a journal of cerebral circulation. 2009. Meschia James F. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The role of HMGCR alternative splicing in statin efficacy. Trends in cardiovascular medicine. 2009. Medina Marisa Wong, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study. Pharmacogenetics and genomics. 2008. Donnelly Louise A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction. European heart journal. 2008. Regieli Jakub J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics: candidate gene identification, functional validation and mechanisms. Human molecular genetics. 2008. Wang Liewei, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER. Atherosclerosis. 2008. Polisecki Eliana, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Common genetic variation in six lipid-related and statin-related genes, statin use and risk of incident nonfatal myocardial infarction and stroke. Pharmacogenetics and genomics. 2008. Hindorff Lucia A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Molecular basis for statin-induced muscle toxicity: implications and possibilities. Pharmacogenomics. 2008. Buettner Catherine, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Family 1 uridine-5'-diphosphate glucuronosyltransferases (UGT1A): from Gilbert's syndrome to genetic organization and variability. Archives of toxicology. 2008. Strassburg Christian P, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effectiveness of statins in the reduction of the risk of myocardial infarction is modified by the GNB3 C825T variant. Pharmacogenetics and genomics. 2008. Peters Bas J M, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation. 2008. Krauss Ronald M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response. Circulation. Cardiovascular genetics. 2008. Voora Deepak, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of APOE genotype on lipid levels in patients with coronary heart disease during a 3-week inpatient rehabilitation program. Clinical pharmacology and therapeutics. 2008. Vossen C Y, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study. Pharmacogenetics and genomics. 2008. Donnelly Louise A, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate. Pharmacogenetics and genomics. 2008. Pasanen Marja K, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
SLCO1B1 variants and statin-induced myopathy--a genomewide study. The New England journal of medicine. 2008. SEARCH Collaborative Group, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Epithelial neutrophil-activating peptide (ENA-78), acute coronary syndrome prognosis, and modulatory effect of statins. PloS one. 2008. Zineh Issam, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients. British journal of clinical pharmacology. 2007. Zhang Wei, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients. Journal of lipid research. 2007. Singer Jonathan B, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenetics and genomics. 2007. Ho Richard H, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clinical pharmacology and therapeutics. 2007. Pasanen M K, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle & nerve. 2007. Ruaño Gualberto, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic determinants of statin intolerance. Lipids in health and disease. 2007. Oh Jisun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Overview of the pharmacoeconomics of pharmacogenetics. Pharmacogenomics. 2006. Dervieux Thierry, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
100 years and counting: prospects for defeating Alzheimer's disease. Science (New York, N.Y.). 2006. Roberson Erik D, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clinical pharmacology and therapeutics. 2006. Niemi Mikko, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes. British journal of clinical pharmacology. 2006. Hedman Mia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy. Arteriosclerosis, thrombosis, and vascular biology. 2006. Berge Knut Erik, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. Clinical pharmacology and therapeutics. 2006. Igel Michael, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenetics and genomics. 2006. Pasanen Marja K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
C-reactive protein levels and outcomes after statin therapy. The New England journal of medicine. 2005. Ridker Paul M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Interindividual differences of response to statin treatment cannot be explained by variations of the human gene for RhoA. Biochemical genetics. 2005. Oliyarnyk Olena, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Variation in the toll-like receptor 4 gene and susceptibility to myocardial infarction. Pharmacogenetics and genomics. 2005. Holloway John W, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
An association study of 43 SNPs in 16 candidate genes with atorvastatin response. The pharmacogenomics journal. 2005. Thompson J F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management. Atherosclerosis. 2004. Kajinami Kouji, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
HMG-CoA reductase inhibitors induce COX-2 gene expression in murine macrophages: role of MAPK cascades and promoter elements for CREB and C/EBPbeta. Experimental cell research. 2004. Chen Jui-Ching, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Statin myotoxicity is associated with changes in the cardiopulmonary function. Atherosclerosis. 2004. Phillips P S, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics. 2004. Niemi Mikko, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA : the journal of the American Medical Association. 2004. Chasman Daniel I, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins. American journal of medical genetics. Part A. 2004. Edison Robin J, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clinical pharmacology and therapeutics. 2004. Mwinyi Jessica, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. The American journal of cardiology. 2004. Jacobson Terry A. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease. American heart journal. 2003. Carlquist John F, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clinical pharmacology and therapeutics. 2003. Nishizato Yohei, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of atorvastatin and pravastatin on serum C-reactive protein. American heart journal. 2003. Kent Steven M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Grapefruit juice and potential drug interactions. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists. 2003. Hare Justin T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effects of simvastatin and atorvastatin on inflammation markers in plasma. Journal of internal medicine. 2002. Wiklund O, et al. PubMed

Clinical Trials

These are trials that mention hmg coa reductase inhibitors and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.